SCHEMBL4841109

SCHEMBL4841109

CCOC(=O)CC(=O)c1c(C(=O)OC)n(C)c2cc(Cl)ccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 6/20 0.50
ALDH1A1 P00352 4/20 0.50
TSHR P16473 2/20 0.50
HSD17B10 Q99714 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
LMNA P02545 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HPGD P15428 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
KDM4E B2RXH2 1/20 0.41
CASP1 P29466 1/20 0.41
MCL1 Q07820 2/20 0.41
TP53 P04637 1/20 0.40
MAPK8 P45983 1/20 0.40
MAPK9 P45984 1/20 0.40
OXER1 Q8TDS5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17959424 0.91 ALOX15 (0.47) ALOX15ALDH1A1TSHRHSD17B10CYP1A2
SCHEMBL5746650 0.86 MAPK8 (0.45) MCL1MAPK8MAPK9OXER1
SCHEMBL4843888 0.85 GAA (0.43) ALOX15ALDH1A1TSHRHSD17B10CYP1A2
SCHEMBL17974081 0.83 ALOX15 (0.44) ALOX15ALDH1A1TSHRHSD17B10CYP1A2
SCHEMBL5702463 0.78 ALOX15 (0.47) ALOX15ALDH1A1TSHRHSD17B10CYP1A2
SCHEMBL3923885 0.78 ALOX15 (0.47) ALOX15ALDH1A1TSHRHSD17B10CYP1A2
SCHEMBL4840274 0.76 MAPK8 (0.40) ALDH1A1TSHRHSD17B10LMNAHPGD
SCHEMBL2085240 0.75 KMT2A (0.48) ALOX15ALDH1A1TSHRHSD17B10CYP1A2
SCHEMBL24482981 0.74 MAPK8 (0.44) ALOX15ALDH1A1TSHRHSD17B10CYP1A2
SCHEMBL3896643 0.73 ALDH1A1 (0.51) ALOX15ALDH1A1TSHRHSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100543016-C Intermediate compounds of 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino [4, 5-b ] indole-1-acetamide derivatives SANOFI AVENTIS (FR) 2009-09-23 CN disclosed
US-20080255129-A1 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-10-16 US disclosed
CN-100406459-C 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino [4, 5-b ] indole-1-acetamide derivatives, their preparation and use in therapy SANOFI AVENTIS (FR) 2008-07-30 CN disclosed
US-7405306-B2 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-07-29 US disclosed
US-20080076775-A1 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-03-27 US disclosed
US-7323467-B2 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-01-29 US disclosed
US-20070219202-A1 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5 b]indole-1-acetamide derivatives, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2007-09-20 US disclosed
US-7235554-B2 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments SANOFI-AVENTIS (FR) 2007-06-26 US disclosed
CN-1970538-A Intermediate compounds of 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino [4, 5-b ] indole-1-acetamide derivatives SANOFI AVENTIS (FR) 2007-05-30 CN disclosed
CN-1656099-A 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino [4, 5-b ] indole-1-acetamide derivatives, their preparation and use in therapy SANOFI AVENTIS (FR) 2005-08-17 CN disclosed
US-20050124615-A1 3-heteroarly-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments SANOFI (FR) 2005-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076775-A1 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics IDO1, IDO2, TPH1 ALOX15 828/4885ALDH1A1 60/4885TSHR 891/4885
US-20050124615-A1 3-heteroarly-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments HRH4, IDO1, HTR4 ALOX15 808/4885ALDH1A1 1008/4885TSHR 2876/4885
US-20070219202-A1 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5 b]indole-1-acetamide derivatives, their preparation and their application in therapeutics IDO1, IDO2, TPH1 ALOX15 1011/4885ALDH1A1 68/4885TSHR 780/4885
US-20080255129-A1 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics IDO1, IDO2, TPH1 ALOX15 828/4885ALDH1A1 60/4885TSHR 891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.